(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 12.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Immunocore Holdings's revenue in 2025 is $333,581,000.On average, 6 Wall Street analysts forecast IMCR's revenue for 2025 to be $18,794,754,107, with the lowest IMCR revenue forecast at $17,823,386,809, and the highest IMCR revenue forecast at $19,450,453,405. On average, 6 Wall Street analysts forecast IMCR's revenue for 2026 to be $20,499,431,628, with the lowest IMCR revenue forecast at $19,028,491,089, and the highest IMCR revenue forecast at $22,439,353,140.
In 2027, IMCR is forecast to generate $24,310,303,908 in revenue, with the lowest revenue forecast at $19,694,588,745 and the highest revenue forecast at $29,115,399,776.